Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507220 | 0.86 | PTPN1 (0.42) | KCNN4L3MBTL1PTPN1CYP3A4CYP2D6 | |
| SCHEMBL28528495 | 0.85 | L3MBTL1 (0.41) | KCNN4L3MBTL1TDP1GRM2CYP3A4 | |
| SCHEMBL28515302 | 0.84 | L3MBTL1 (0.46) | KCNN4L3MBTL1TDP1GRM2CYP3A4 | |
| SCHEMBL29381303 | 0.81 | L3MBTL1 (0.42) | KCNN4L3MBTL1TDP1PTPN1GRM2 | |
| SCHEMBL20608004 | 0.81 | L3MBTL1 (0.42) | KCNN4L3MBTL1TDP1PTPN1GRM2 | |
| SCHEMBL4535910 | 0.81 | L3MBTL1 (0.55) | KCNN4L3MBTL1TDP1CYP2D6CYP2C19 | |
| SCHEMBL9082172 | 0.81 | PTPN1 (0.39) | L3MBTL1TDP1PTPN1CYP3A4CYP2D6 | |
| SCHEMBL29617898 | 0.80 | L3MBTL1 (0.58) | KCNN4L3MBTL1TDP1CYP3A4CYP2D6 | |
| SCHEMBL12772061 | 0.80 | L3MBTL1 (0.58) | KCNN4L3MBTL1TDP1CYP3A4CYP2D6 | |
| SCHEMBL19617278 | 0.79 | PTPN1 (0.49) | KCNN4L3MBTL1TDP1PTPN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4216951-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220298174-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| EP-4011886-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022087371-A1 | NOVEL BICYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021052499-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| WO-2021023154-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-02-11 | — | — | WO | disclosed |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | PHARMACYCLICS LLC | 2006-09-14 | — | — | US | disclosed |
| EP-1204660-B1 | SEROTONERGIC BENZOTHIOPHENES | LILLY CO ELI (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1204660-A1 | SEROTONERGIC BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001009126-A1 | SEROTONERGIC BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389029-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | KCNN4 1962/4885L3MBTL1 4584/4885TDP1 3665/4885 |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | F7, F9, F5 | KCNN4 4320/4885L3MBTL1 4480/4885TDP1 2384/4885 |
| US-20230357277-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | KCNN4 4825/4885L3MBTL1 2705/4885TDP1 2944/4885 |
| US-20230227472-A1 | FUSED PYRIDONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, WEE1 | KCNN4 1962/4885L3MBTL1 4584/4885TDP1 3665/4885 |
| US-20220298174-A1 | TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | KCNN4 4125/4885L3MBTL1 4301/4885TDP1 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.